Stock Price, News, Quote and Profile of GELESIS HOLDINGS INC(NYSE:GLS) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GELESIS HOLDINGS INC

NYSE:GLS (4/10/2023, 7:04:01 PM)

After market: 0.1555 0 (-1.95%)

0.1586

+0 (+0.38%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap11.63M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.

Company Info

GELESIS HOLDINGS INC

501 Boylston Street, Suite 6102

Boston MASSACHUSETTS

P: 18573277737.0

Employees: 93

Website: https://capstarspac.com/

GLS News

a year ago - Seeking AlphaNYSE to suspend trading immediately in Gelesis Holdings

Trading in Gelesis Holdings (GLS) will be suspended immediately by the NYSE as NYSE has determined to commence proceedings to delist the common stock as Company's global...